Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MiRNA expression screening in Liver X Receptor (NR1H3) agonist (GW3965) -treated differentiated Caco-2/TC7 cells

ABSTRACT: Differentiated human enterocytic Caco-2/TC7 cells grown on transwell were incubated with LXR agonist GW3965 (5µM) or Vehicle DMSO (1:2000 ; vol:vol) for 48 hours. Total RNA were extracted using mirVana miRNA Isolation Kit (life technologies) then processed with Flash Tag Biotin HSR kit (Affymetrix) and hybridized on an Affymetrix GeneChip miRNA 4.0 Array.

ORGANISM(S): Homo sapiens

SUBMITTER: Olivier Briand

PROVIDER: E-MTAB-3675 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Transcriptional regulation of genes in AML12 cells treated with Palmitic acid, LXR lingand (GW3965) and Ulk1 siRNA

Project description:Transcriptional regulation of genes in AML12 cells treated with Palmitic acid, LXR lingand (GW3965) and Ulk1 siRNA shows differential effect of Ulk1 KD on LXr responsive genes AML-12 cells co-treated with 0.75mM PA+/- 10ÂµM GW3965 for 24 h +/- Ulk1 SiRNA

2016-03-31 | E-GEOD-74059 | biostudies-arrayexpress

Genome-wide analysis of GW3965-responsive genes in 4 different breast cancer cell lines, MCF-7, T-47D, SK-BR-3, and MDA-MB-231

Project description:Analysis of differentially expressed genes in response to the LXR agonist GW3965 in the MCF-7, T-47D, SK-BR-3, and MDA-MB-231 breast cancer cell lines. It was previously reported that GW3965 has antiproliferative effects on these 4 different breast cancer cell lines. In the present study, we additionally determine the effects of the LXR ligand on breast cancer cells and determine their mechanism of action in reducing cell proliferation. Total RNA obtained from 4 different breast cancer cell lines (MCF-7, T-47D, SK-BR-3, MDA-MB-231) grown in culture treated with ethanol (control) or GW3965 (GW-treated, experimental) for 48 hours. Triplicates were performed.

2013-07-17 | E-GEOD-34987 | biostudies-arrayexpress

MPGWIFN

Project description:Bone marrow derived macrophages were treated with 2 micromolar GW3965 or vehicle for 18 hours and then stimulated with IFN-gamma (5ng/ml) or PBS for 6 hours.

2013-06-27 | E-MEXP-3871 | biostudies-arrayexpress

RNAseq PC3 DMSO vs GW3965

Project description:RNAseq PC3 DMSO vs GW3965

| PRJNA1029015 | ENA

RNA-seq of primary human CD4+ T cells treated with the LXR agonist GW3965, with and without TCR stimulation

Project description:We used RNA-sequencing to determine the transcriptional response to liver X receptor (LXR) activation in primary human CD4+ T cells, both at rest and under activation conditions. CD4+ T cells were isolated from 3 healthy donors and treated with the synthetic LXR agonist GW3965 (GW) for 24 hours. Gene expression was compared to control samples (CTRL) treated with the LXR antagonist GSK1440233. To activate the T cell antigen receptor (TCR), cells were pre-treated with CTRL/GW alone for 6 hours then transferred to plates containing anti-CD3 and anti-CD28 for a further 18 hours.

2021-04-30 | E-MTAB-9141 | biostudies-arrayexpress

Transcription profiling of human enterocytes cultured with different dietary lipids

Project description:The present study aimed to identify the specific impact of dietary lipids-containing micelles on gene expression in enterocytes.

2008-08-27 | E-MEXP-1446 | biostudies-arrayexpress

Mouse Hepatocytes +/- GW

Project description:Identification of novel LXR target genes Primary mouse hepatocytes were isolated from Bl6 mice and plated on 6 well plates. Cells serum starved and treated with statin/MVA followed by overnight adminstration of DMSO or LXR agonist GW3965. Total RNA isolation using TRIZOL and Qiagen Column.

2016-03-31 | E-GEOD-77786 | biostudies-arrayexpress

Broad-Spectrum Therapeutic Suppression of Metastatic Melanoma Through Nuclear Hormone Receptor Activation

Project description:Melanoma metastasis is a devastating outcome in need of novel preventive therapies. We provide pharmacologic, nolecuar, and genetic evidence establishing the liver-X nuclear hormone receptor (LXR) as a therapeutic target in melanoma. Molecular and genetic experiments revealed these effects to be mediated by LXRb, which elicits these outcomes through transcriptional induction of tumoral and systemic apolipoprotein-E (ApoE). LXRb agonism robustly suppressed tumor growth and metastasis across a wide spectrum of melanoma lines of diverse mutational subtypes established in xenograft, immunocompetent, and genetically-initiated model. We propose a path for the clinical testing of LXRb targeting-a therapeutic approach that uniquely acts by transcriptionally acivating a metastasis suppressor gene. In this experiment we analyzed the effect of GW3965 treatment on gene expression in the MeWo human melanoma cell line. The cells were treated either with DMSO or GW3965 at 1 micromolar for 48 hours, after which the RNA was extracted and gene expression was analyzed by transcriptomic profiling

2014-06-01 | E-GEOD-48782 | biostudies-arrayexpress

Bulk RNA-seq of intestinal organoids upon treatment with LXR agonist GW3965

Project description:Liver X Receptor (LXR) activation in intestinal epithelial organoids promotes their growth in vitro. To investigate the downstream effect of LXR activation in intestinal epithelial cells and identify potential pathways driving regeneration, we carried out an unbiased transcriptomic analysis of intestinal epithelial organoids stimulated with the LXR agonist GW3965. In detail, wild type small intestinal crypts were seeded in vitro and stimulated with vehicle (DMSO) or GW3965. After six hours, closing crypts (organoids) were collected for RNA extraction and were analyzed by RNA sequencing.

2023-06-11 | GSE152283 | GEO

Intestine-specific activation of LXR via low-dose oral administration of GW3965

Project description:Generation of high density lipoprotein (HDL) requires apoA1 and the cholesterol transporter ABCA1. Although the liver generates most HDL in blood, small intestines also can synthesize HDL. However, distinct functions for intestinal HDL are unknown. Here we designed intestine-specific activation of LXR via low-dose administration of GW3965, LXR agonist. The liver status was improved by therapeutics that elevated and depended upon intestinal HDL production via GW3965. Thus, protection of the liver from injury in response to gut-derived signals like LPS is a major function of intestinally synthesized HDL.

2021-10-06 | GSE167983 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data